Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiosyentBIOYF +0.86%98 EV-to-EBIT is 13.06 as of Aug. 03, 2026, which is 13% above its 10-year median of 11.51. GuruFocus rates BIOYF with a GF Score™ of 98/100 and a GF Value™ of $12.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 691 Drug Manufacturers companies, Biosyent ranks better than 57.45% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biosyent's Enterprise Value for the quarter that ended in Mar. 2026 was $113.72 Mil.
Biosyent's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent EV-to-EBIT Related Terms
Biosyent EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biosyent's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biosyent's EV-to-EBIT falls into.
Biosyent's current Enterprise Value is $116.08 Mil.
Biosyent's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (BIOYF) has a EV-to-EBIT of 13.06 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biosyent and its competitors. This is 13% above median its historical median of 11.51. Over the past decade, Biosyent's EV-to-EBIT has ranged from 4.60 to 22.70. According to the industry distribution chart, Biosyent ranks #294 out of 691 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Biosyent's EV-to-EBIT too high?
Biosyent's current EV-to-EBIT of 13.06 is 13% above median its 10-year median of 11.51. Over the past 10 years, this metric has ranged from a low of 4.60 to a high of 22.70. The Drug Manufacturers industry median EV-to-EBIT is 15.59. Biosyent's value of 13.06 is 16.2% below this industry median. Based on the distribution chart, Biosyent ranks #294 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biosyent has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #294 out of 691 companies for EV-to-EBIT. This puts Biosyent in the upper half of its industry. The industry median EV-to-EBIT is 15.59. Biosyent's value of 13.06 is 16.2% below this benchmark. Historically, Biosyent's own EV-to-EBIT has ranged from 4.60 to 22.70 over the past decade. While the company's 10-year median is 11.51 vs. the industry median of 15.59, Biosyent has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.59, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current EV-to-EBIT of 13.06 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current EV-to-EBIT is 13.06, which is 13% above median its own 10-year median of 11.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (BIOYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.05, compared to a current price of $10.53 — trading 12.6% below its estimated fair value. The current EV-to-EBIT is 13.06, which is 13% above median its 10-year median of 11.51 and 16.2% below the Drug Manufacturers industry median of 15.59. Biosyent's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biosyent (BIOYF), the current EV-to-EBIT is 13.06 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (BIOYF) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of $10.53 is trading 12.6% below its estimated GF Value™ of $12.05.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for BIOYF:
EV-to-EBIT: 13.06 (13% above median its 10-year median of 11.51)
GF Value™: $12.05 vs. price of $10.53 (12.6% below fair value)
Industry Position: 16.2% below the Drug Manufacturers median (#294 of 691)
No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score
Get the complete analysis for BIOYF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOYF has been successfully added to your 
